Cresco Labs (CRLBF) Non-Current Deferred Tax Liability (2019 - 2026)
Cresco Labs' (CRLBF) quarterly Non-Current Deferred Tax Liability came in at $33.8 million in Q1 2026, down 11.7% YoY from $38.3 million in Q1 2025, and up 0.54% on a QoQ basis from $33.6 million in Q4 2025.
Cresco Labs (CRLBF) Non-Current Deferred Tax Liability (2019 - 2026) Analysis & Trends
Cresco Labs (CRLBF) has 8 years of Non-Current Deferred Tax Liability data on file, last reported at $33.8 million in Q1 2026.
- Quarterly Non-Current Deferred Tax Liability fell 11.7% year-over-year to $33.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $33.8 million (down 11.7% YoY) and the FY2025 annual result came in at $33.6 million, changed N/A from the prior year.
- Non-Current Deferred Tax Liability grew to $33.8 million in Q1 2026, from $33.6 million in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $84.2 million in Q1 2022 to a low of $33.6 million in Q4 2025.
- A 5-year average of $53.8 million and a median of $41.3 million in 2024 frame the typical range for Non-Current Deferred Tax Liability.
- Annual changes were most pronounced in 2022 — Non-Current Deferred Tax Liability soared 93.39% — and 2023, when it plunged 46.16%.
- Tracing CRLBF's Non-Current Deferred Tax Liability over 5 years: stood at $75.1 million in 2022, then sank by 46.16% to $40.5 million in 2023, then grew by 1.06% to $40.9 million in 2024, then declined by 17.78% to $33.6 million in 2025, then climbed by 0.54% to $33.8 million in 2026.
- The last three Non-Current Deferred Tax Liability figures came in at $33.8 million (Q1 2026), $33.6 million (Q4 2025), and $38.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - |
| 10 | Cresco Labs | 295.09 Mn | 230.98 Mn | 86.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 33.80 Mn |
| Mar 31, 2026 | 33.80 Mn |
| Dec 31, 2025 | 33.62 Mn |
| Dec 31, 2025 | 33.62 Mn |
| Sep 30, 2025 | 38.50 Mn |
| Sep 30, 2025 | 38.50 Mn |
| Jun 30, 2025 | 38.82 Mn |
| Jun 30, 2025 | 38.82 Mn |
| Mar 31, 2025 | 38.28 Mn |
| Mar 31, 2025 | 38.28 Mn |
| Sep 30, 2024 | 40.89 Mn |
| Sep 30, 2024 | 40.89 Mn |
| Jun 30, 2024 | 41.59 Mn |
| Jun 30, 2024 | 41.59 Mn |
| Mar 31, 2024 | 40.98 Mn |
| Mar 31, 2024 | 40.98 Mn |
| Dec 31, 2023 | 40.46 Mn |
| Dec 31, 2023 | 40.46 Mn |
| Sep 30, 2023 | 45.35 Mn |
| Sep 30, 2023 | 45.35 Mn |